Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.
Arthritis Rheumatol
; 71(4): 626-631, 2019 04.
Article
em En
| MEDLINE
| ID: mdl-30468001
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Fármacos Dermatológicos
/
Ustekinumab
/
Entesopatia
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Guideline
/
Observational_studies
/
Risk_factors_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article